The Company and Basis of Presentation (Details)				1 Months Ended	6 Months Ended
	Jun. 27, 2024 USD ($) Rate	Jan. 18, 2024 USD ($) $ / shares shares	Jan. 02, 2024 USD ($)	Aug. 31, 2019 patient	Jun. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 $ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Estimated number of study patients | patient				14,000
Collaborations with Third Parties
First milestone payment			$ 100,000,000
Time required to pay cash portion			15 days
Second milestone payment			$ 25,000,000
Common stock, par value (in dollars per share) | $ / shares					$ 0.001	$ 0.001
Revenue Interest Purchase Agreement (RIPA)
Collaborations with Third Parties
Repurchase consideration	$ 343,750,000				$ 343,750,000
Sale of Future Royalties
Collaborations with Third Parties
Consideration received	$ 304,656,180
Percent acquired	100.00%
Threshold ratio of purchase price | Rate	1.700
Aggregate principal amount	$ 517,915,506
Interests reverted to company	100.00%
Commitment Offering
Collaborations with Third Parties
Issued stock (in shares) | shares		56,700,000
Common stock, par value (in dollars per share) | $ / shares		$ 0.001
Price per share (in dollars per share) | $ / shares		$ 1.50
Proceeds from stock offering, net		$ 90,700,000
Estimated offering expenses		$ 7,100,000
Over-Allotment Option
Collaborations with Third Parties
Issued stock (in shares) | shares		8,505,000
Option period		30 days
Minimum
Collaborations with Third Parties
Aggregate payment agreement			$ 125,000,000